Additionally, the majority of cell types on the airway surfaces that are accessible to CFTR gene transfer vectors are terminally differentiated with a defined lifespan; thus, gene therapy necessitates repeat dosing to achieve unintermitted CFTR expression in the lungs with CF. This evidence concerns the gene CFTR and cystic fibrosis.